BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research note issued to investors on Monday.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 2nd. Cowen reissued a hold rating and set a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 6th. Zacks Investment Research lowered Regeneron Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, January 5th. Leerink Swann raised their target price on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the stock an outperform rating in a research report on Monday, October 1st. Finally, ValuEngine raised Regeneron Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, December 15th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $404.11.

NASDAQ REGN traded down $1.69 on Monday, reaching $406.37. 26,408 shares of the stock traded hands, compared to its average volume of 715,941. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. The firm has a market cap of $43.24 billion, a P/E ratio of 30.25, a PEG ratio of 1.72 and a beta of 1.14. Regeneron Pharmaceuticals has a 12 month low of $281.89 and a 12 month high of $416.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.94 by $0.93. The firm had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period last year, the company posted $3.99 EPS. On average, research analysts predict that Regeneron Pharmaceuticals will post 18.88 earnings per share for the current fiscal year.

In other news, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the transaction, the vice president now directly owns 9,871 shares in the company, valued at $3,543,392.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.42% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its position in Regeneron Pharmaceuticals by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 171,861 shares of the biopharmaceutical company’s stock worth $59,287,000 after buying an additional 2,191 shares in the last quarter. Gabelli Funds LLC grew its position in Regeneron Pharmaceuticals by 38.9% during the second quarter. Gabelli Funds LLC now owns 2,500 shares of the biopharmaceutical company’s stock worth $862,000 after buying an additional 700 shares in the last quarter. BlueMountain Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $349,000. Baird Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 4.6% during the second quarter. Baird Financial Group Inc. now owns 17,826 shares of the biopharmaceutical company’s stock worth $6,150,000 after buying an additional 779 shares in the last quarter. Finally, BB&T Securities LLC grew its position in Regeneron Pharmaceuticals by 54.6% during the second quarter. BB&T Securities LLC now owns 11,440 shares of the biopharmaceutical company’s stock worth $3,946,000 after buying an additional 4,038 shares in the last quarter. Institutional investors and hedge funds own 67.20% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.